MGI Announces Commercial Launch of HotMPS High-Throughput Sequencing Kit* and Instrument** in Germany
Retrieved on:
Tuesday, September 6, 2022
Software, Enzyme, Medical genetics, Technology, BGI Group, Research, Agriculture, YouTube, Wehrheim, Precision medicine, Nucleotide, University, LinkedIn, MUST, Centre for Applied Genomics, Laboratory, Patent, CPAS, Annual general meeting, MEDICA, Conference, Twitter, Risk, Institute, MGI, International Conference on Availability, Reliability and Security, General manager, Fine chemical, Hydraulic machinery, Genomics, European
WEHRHEIM, Germany, Sept. 6,2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has announced the commercial availability of its innovative HotMPS reagents* and sequencing instrument** in Germany as of 9 August 2022.
Key Points:
- WEHRHEIM, Germany, Sept. 6,2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, has announced the commercial availability of its innovative HotMPS reagents* and sequencing instrument** in Germany as of 9 August 2022.
- Meanwhile, the DNBSEQ-G400** sequencing platform (for HotMPS exclusively) will be presented at MEDICA 2022 on 14-17 November in Dsseldorf.
- MGI will also attend the 32nd GfH Annual Meeting on 15-17 March 2023 in Kassel as a sponsor.
- "As our trusted partner, we are excited about MGI's HotMPS chemistry* arriving in Germany and the new research advances it will enable."